Catechol-O-Methyltransferase in Parkinson’s Disease

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The introduction of levodopa therapy for Parkinson’s disease (PD), initially by Birkmayer and colleagues in 1961 and Barbeau and colleagues in 1962, and in its ultimately successful form by Cotzias and colleagues in 1967, still represents the defining landmark in the treatment of PD (1-3). This dramatic advance was preceded by methodical basic laboratory research in the late 1950s and early 1960s, which formed a groundwork documenting the presence of striatal dopamine deficiency in PD (4-8) and paved the road for the application of this knowledge in the clinical arena.

Original languageEnglish (US)
Title of host publicationHandbook of Parkinson's Disease, Third Edition
PublisherCRC Press
Pages437-451
Number of pages15
ISBN (Electronic)9780203912164
ISBN (Print)9780824742423
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Corpus Striatum
Catechol O-Methyltransferase
Levodopa
Parkinson Disease
Dopamine
Research
Therapeutics
Parkinson Disease 8
Parkinson disease 3

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pfeiffer, R. (2003). Catechol-O-Methyltransferase in Parkinson’s Disease. In Handbook of Parkinson's Disease, Third Edition (pp. 437-451). CRC Press.

Catechol-O-Methyltransferase in Parkinson’s Disease. / Pfeiffer, Ronald.

Handbook of Parkinson's Disease, Third Edition. CRC Press, 2003. p. 437-451.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pfeiffer, R 2003, Catechol-O-Methyltransferase in Parkinson’s Disease. in Handbook of Parkinson's Disease, Third Edition. CRC Press, pp. 437-451.
Pfeiffer R. Catechol-O-Methyltransferase in Parkinson’s Disease. In Handbook of Parkinson's Disease, Third Edition. CRC Press. 2003. p. 437-451
Pfeiffer, Ronald. / Catechol-O-Methyltransferase in Parkinson’s Disease. Handbook of Parkinson's Disease, Third Edition. CRC Press, 2003. pp. 437-451
@inbook{5e47ac8228b644a4966ff17da4751e2a,
title = "Catechol-O-Methyltransferase in Parkinson’s Disease",
abstract = "The introduction of levodopa therapy for Parkinson’s disease (PD), initially by Birkmayer and colleagues in 1961 and Barbeau and colleagues in 1962, and in its ultimately successful form by Cotzias and colleagues in 1967, still represents the defining landmark in the treatment of PD (1-3). This dramatic advance was preceded by methodical basic laboratory research in the late 1950s and early 1960s, which formed a groundwork documenting the presence of striatal dopamine deficiency in PD (4-8) and paved the road for the application of this knowledge in the clinical arena.",
author = "Ronald Pfeiffer",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780824742423",
pages = "437--451",
booktitle = "Handbook of Parkinson's Disease, Third Edition",
publisher = "CRC Press",

}

TY - CHAP

T1 - Catechol-O-Methyltransferase in Parkinson’s Disease

AU - Pfeiffer, Ronald

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The introduction of levodopa therapy for Parkinson’s disease (PD), initially by Birkmayer and colleagues in 1961 and Barbeau and colleagues in 1962, and in its ultimately successful form by Cotzias and colleagues in 1967, still represents the defining landmark in the treatment of PD (1-3). This dramatic advance was preceded by methodical basic laboratory research in the late 1950s and early 1960s, which formed a groundwork documenting the presence of striatal dopamine deficiency in PD (4-8) and paved the road for the application of this knowledge in the clinical arena.

AB - The introduction of levodopa therapy for Parkinson’s disease (PD), initially by Birkmayer and colleagues in 1961 and Barbeau and colleagues in 1962, and in its ultimately successful form by Cotzias and colleagues in 1967, still represents the defining landmark in the treatment of PD (1-3). This dramatic advance was preceded by methodical basic laboratory research in the late 1950s and early 1960s, which formed a groundwork documenting the presence of striatal dopamine deficiency in PD (4-8) and paved the road for the application of this knowledge in the clinical arena.

UR - http://www.scopus.com/inward/record.url?scp=85056275326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056275326&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85056275326

SN - 9780824742423

SP - 437

EP - 451

BT - Handbook of Parkinson's Disease, Third Edition

PB - CRC Press

ER -